Stimulation of growth hormone release by vasoactive intestinal peptide and peptide PHI in rat anterior pituitary reaggregates. Permissive action of a glucocorticoid and inhibition by thyrotropin-releasing hormone.

Denef C, Schramme C, Baes M

Neuroendocrinology1 Jan 1985Cited by 21 (Europe PMC)

PMID3918279DOI10.1159/000124057PepBankPUB-03918279

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In superfused rat anterior pituitary reaggregates, VIP stimulated prolactin release in a concentration-dependent manner.
In plain wordsIn rat pituitary cells in culture, VIP made the cells release more prolactin as the dose went up.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseProlactin release
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
Report a problemFND-0391827901
02LabIn vitro (cells)Activity measurement
In rat anterior pituitary reaggregates without dexamethasone, VIP had only a marginal effect on growth hormone release.
In plain wordsIn rat pituitary cells in culture, VIP barely changed growth hormone release when no dexamethasone was present.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeGrowth hormone release without dexamethasone
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
Report a problemFND-0391827902
03LabIn vitro (cells)Activity measurement
In rat anterior pituitary reaggregates cultured with 80 nM dexamethasone, VIP strongly stimulated growth hormone release from a concentration as low as 0.1 nM.
In plain wordsIn rat pituitary cells in culture with dexamethasone present, VIP strongly raised growth hormone release at very low doses.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseGrowth hormone release with dexamethasone
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
from 0.1 nMAs given in this study (rat).
Source sentences
Summary
When reaggregates were cultured in the presence of 80 nM dexamethasone (Dex) VIP strongly stimulated GH release from a concentration as low as 0.1 nM.
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
Report a problemFND-0391827903
04LabIn vitro (cells)Activity measurement
In rat anterior pituitary reaggregates, VIP did not stimulate LH release.
In plain wordsIn rat pituitary cells in culture, VIP did not make the cells release LH.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeLH release
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
VIP did not stimulate LH release.
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
Report a problemFND-0391827904
05LabIn vitro (cells)Activity measurement
In rat anterior pituitary reaggregates, GRF stimulated growth hormone release more potently and with higher intrinsic activity than VIP.
In plain wordsIn rat pituitary cells in culture, VIP raised growth hormone less strongly than GRF did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableGrowth hormone release, VIP versus GRF
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Comparator
GH-releasing factor (GRF)
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
GH-releasing factor (GRF) stimulated GH more potently and with higher intrinsic activity than VIP
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
Report a problemFND-0391827906

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In rat anterior pituitary reaggregates, TRH strongly inhibited VIP-stimulated growth hormone release.
In plain wordsIn rat pituitary cells in culture, TRH strongly reduced the growth hormone release that VIP had caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseVIP-stimulated growth hormone release with TRH
Study
ratn: not reported in source
Superfused rat anterior pituitary cell reaggregates
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
and strongly inhibited VIP-stimulated GH release.
1 context sentence(design, population, supporting numbers)
Summary · context
In superfused rat anterior pituitary cell reaggregates, cultured for 5 days in serum-free defined medium, vasoactive intestinal peptide (VIP) concentration-dependently stimulated prolactin (Prl) release but had only a marginal effect on growth hormone (GH) release.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0391827905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.